---
title: "MGC Pharmaceuticals 'in a race to get as much applications for CimetrA so we can open in 2022'"
image: "https:\/\/i.ytimg.com\/vi\/xrkWWiqIYDE\/hqdefault.jpg"
vid_id: "xrkWWiqIYDE"
categories: "News-Politics"
tags: ["Pharmaceuticals","applications","CimetrA"]
date: "2021-12-10T08:47:27+03:00"
vid_date: "2021-12-08T14:41:54Z"
duration: "PT5M45S"
viewcount: "206"
likeCount: ""
dislikeCount: ""
channel: "Proactive"
---
{% raw %}MGC Pharmaceuticals Ltd's (LSE:MXC, OTC:MGCLF, ASX:MXC) Roby Zomer joins Proactive London to talk about their raise of £5.5mln via a share placing – cash that will be used to fund emergency use authorisation applications for the use of its lead asset in COVID.<br /><br />It said it plans to begin the approval process for CimetrA in India before rolling it out to a total of five countries in central and eastern Europe and central Asia.<br /><br />CimetrA is a pharmaceutical synthetic composition of Curcumin and Boswellia that is thought to have an anti-inflammatory effect as well as potentially modulating the immune system.{% endraw %}
